Abnormalities of the Mitral Apparatus in Hypertrophic Cardiomyopathy: Echocardiographic, Pathophysiologic, and Surgical Insights

Silbiger, Jeffrey J.

doi:10.1016/j.echo.2016.03.003

Cited by 64 publications

(37 citation statements)

References 128 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…HCM, on echocardiographic evaluation, is characterized by a maximal left ventricular wall thickness > 15 mm, with almost one third having wall thickening localized to a single segment, which may be isolated to the apex, in the absence of any identifiable cause for the hypertrophy (Maron et al, 2014;Silbiger, 2016). As many as 70% of patients with HCM may have SAM causing a dynamic obstruction of the left ventricle outflow tract, which may be accompanied by anatomic abnormalities of the mitral apparatus (Silbiger, 2016).…”

Section: Discussionmentioning

confidence: 99%

Stress Cardiomyopathy in a Patient with Hypertrophic Cardiomyopathy: Case Presentation and Review of the Literature

Vinardell

Mihos

Nader

et al. 2018

Rev. Cardiovasc. Med.

View full text Add to dashboard Cite

Stress cardiomyopathy and hypertrophic cardiomyopathy are two distinct entities with different pathophysiologic causes. In the recent medical literature their concurrency has been described. During the acute phase of a stress cardiomyopathy making the diagnosis of a concomitant hypertrophic cardiomyopathy may be challenging, and has important implications in both the acute and longterm clinical management. Herein, we present a case of a stress cardiomyopathy occurring in a patient with hypertrophic cardiomyopathy, along with a review of the literature.

show abstract

Section: Discussionmentioning

confidence: 99%

Stress Cardiomyopathy in a Patient with Hypertrophic Cardiomyopathy: Case Presentation and Review of the Literature

Vinardell

Mihos

Nader

et al. 2018

Rev. Cardiovasc. Med.

View full text Add to dashboard Cite

show abstract

“…74 Another limitation of current SRTs is that they do not typically address mitral valve pathology that is highly prevalent in HCM. This includes abnormalities of the mitral leaflets (elongation) and subvalvular apparatus (displacement or abnormal insertion of chordae/papillary muscles) [75][76][77] that have been shown to independently contribute to LVOT obstruction. 78 Several novel procedural techniques attempt to address these limitations (Figure 1).…”

Section: Novel Procedural Techniques For Hypertrophic Cardiomyopathymentioning

confidence: 99%

Hypertrophic cardiomyopathy: the future of treatment

Tuohy

Kaul

Song

et al. 2020

European J of Heart Fail

122

View full text Add to dashboard Cite

Hypertrophic cardiomyopathy (HCM) is a heterogeneous genetic disorder most often caused by sarcomeric mutations resulting in left ventricular hypertrophy, fibrosis, hypercontractility, and reduced compliance. It is the most common inherited monogenic cardiac condition, affecting 0.2% of the population. Whereas currently available therapies for HCM have been effective in reducing morbidity, there remain important unmet needs in the treatment of both the obstructive and non‐obstructive phenotypes. Novel pharmacotherapies directly target the molecular underpinnings of HCM, while innovative procedural techniques may soon offer minimally‐invasive alternatives to current septal reduction therapy. With the advent of embryonic gene editing, there now exists the potential to correct underlying genetic mutations that may result in disease. This article details the recent developments in the treatment of HCM including pharmacotherapy, septal reduction procedures, mitral valve manipulation, and gene‐based therapies.

show abstract

“…Some authors believe that the hypertrophy of one or two papillary muscles up to 1.1 cm in either vertical or horizontal diameters can be a manifestation of independent HCM phenotype [18,28]. However, current literature data on the involvement of anterior cusp of the mitral valve in the pathogenesis of heart failure in HCM [4,[29][30][31][32][33] presuppose that changes in papillary muscles may be secondary to the morphofunctional features of the cusps and chordae of the mitral valve in this pathology.…”

Section: The Objectivementioning

confidence: 99%

Myocardial morphology in hypertrophic cardiomyopathy: the current state of the problem

Balabai

2019

ZMJ

View full text Add to dashboard Cite

Цель работы -на основании данных современных источников научной литературы проанализировать морфологические особенности миокарда при гипертрофической кардиомиопатии.Обзор освещает современные взгляды на особенности структурного ремоделирования миокарда левого желудочка сердца у больных гипертрофической кардиомиопатией, приведены наиболее распространенные классификации данной патологии. Уделено внимание проблеме взаимосвязи фигур дизарея кардиомиоцитов и фиброза миокарда. Важное патогенетическое звено развития сердечной недостаточности, усиливающее связь между нарушениями гистоархитектоники миокарда и прогрессирующей ишемией сердца при гипертрофической кардиомиопатии -«болезнь малых сосудов».Выводы. Несмотря на большое количество исследований гипертрофической кардиомиопатии, в научной литературе нет единого мнения об этиологии и патогенезе гипертрофической кардиомиопатии. Противоречивые сведения о наличии взаимосвязи и последовательности развития фигур дизарея, гипертрофии кардиомиоцитов, интерстициального фиброза, изменений микроциркуляторного русла и митрального клапана при гипертрофической кардиомиопатии затрудняют поиски адекватного этиотропного лечения. Полиморфизм клинических и морфологических проявлений гипертрофической кардио миопатии требует от кардиологов и патогистологов совместных усилий по изучению данной болезни.A -research concept and design; B -collection and/or assembly of data; C -data analysis and interpretation; D -writing the article; E -critical revision of the article; F -final approval of the article The objective. Based on the modern sources of scientific data to analyze the morphological features of the myocardium in hypertrophic cardiomyopathy.The paper presents a literature review on current views on the features of structural remodeling of the left ventricular myocardium in patients with hypertrophic cardiomyopathy, as well as the most common classifications of this pathology. The emphasis is made on the problem of the interrelation of myocardial disarray and fibrosis.The "small vessel disease" is an important pathogenetic link in the development of heart failure, which enhances the relation between disorder of myocardial histoarchitectonics and progressive cardiac ischemia in hypertrophic cardiomyopathy. Conclusions.Notwithstanding the numerous research data on hypertrophic cardiomyopathy, no consensus among the authors regarding the etiology and pathogenesis of hypertrophic cardiomyopathy exists to date. Controversial data on the interrelation and sequence of disarray, myocardial hypertrophy, interstitial fibrosis, changes in the microvasculature and structural changes of the mitral valve in patients with hypertrophic cardiomyopathy hamper the search for adequate etiotropic treatment.Polymorphism of clinical and morphological manifestations of hypertrophic cardiomyopathy requires collaborative efforts to study the disease by cardiologists and pathologists.Морфологія міокарда при гіпертрофічній кардіоміопатії: сучасний стан проблеми А. А. Балабай Мета роботи -на підставі даних сучасни...

show abstract

Abnormalities of the Mitral Apparatus in Hypertrophic Cardiomyopathy: Echocardiographic, Pathophysiologic, and Surgical Insights

Cited by 64 publications

References 128 publications

Stress Cardiomyopathy in a Patient with Hypertrophic Cardiomyopathy: Case Presentation and Review of the Literature

Stress Cardiomyopathy in a Patient with Hypertrophic Cardiomyopathy: Case Presentation and Review of the Literature

Hypertrophic cardiomyopathy: the future of treatment

Myocardial morphology in hypertrophic cardiomyopathy: the current state of the problem

Contact Info

Product

Resources

About